Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593101 | 0.82 | COMT (0.49) | COMTNPC1RAB9AMAPTERN1 | |
| SCHEMBL3593513 | 0.79 | COMT (0.47) | COMTNPC1RAB9AMAPTPOLB | |
| SCHEMBL3596419 | 0.78 | COMT (0.47) | COMTNPC1RAB9AMAPTS1PR1 | |
| SCHEMBL3588577 | 0.77 | COMT (0.55) | COMTNPC1RAB9AMAPTERN1 | |
| SCHEMBL3586303 | 0.77 | COMT (0.48) | COMTNPC1RAB9AMAPTS1PR1 | |
| SCHEMBL3587756 | 0.77 | COMT (0.49) | COMTNPC1RAB9AMAPTPOLB | |
| SCHEMBL3594046 | 0.77 | COMT (0.46) | COMTNPC1RAB9AMAPTS1PR1 | |
| SCHEMBL1446844 | 0.76 | COMT (0.56) | COMTNPC1RAB9AMAPTERN1 | |
| SCHEMBL3587510 | 0.75 | COMT (0.56) | COMTNPC1RAB9AMAPTERN1 | |
| SCHEMBL1447359 | 0.75 | COMT (0.49) | COMTNPC1RAB9AMAPTS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | COMT 10/4885NPC1 90/4885RAB9A 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.